|
|
||||||||
and -1ß in Macrophages1


*
Laboratory of Molecular Biology, G. Gaslini Institute, Genova, Italy;
DTP-Tumor Hypoxia Program and
Laboratory of Experimental Immunology, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, MD 21702
We previously found that the tryptophan catabolite picolinic acid
(PA) is a costimulus for the activation of macrophage effector
functions. In this study, we have investigated the ability of PA to
modulate the expression of chemokines in macrophages. We demonstrate
that PA is a potent activator of the inflammatory chemokines MIP
(macrophage inflammatory protein)-1
and MIP-1ß (MIPs) mRNA
expression in mouse macrophages in a dose- and time-dependent fashion
and through a de novo protein synthesis-dependent process. The
induction by PA occurred within 3 h of treatment and reached a
peak in 12 h. The stimulatory effects of PA were selective for
MIPs because other chemokines, including monocyte chemoattractant
protein-1, RANTES, IFN-
-inducible protein-10, MIP-2, and
macrophage-derived chemokine, were not induced under the same
experimental conditions and were not an epiphenomenon of macrophage
activation because IFN-
did not affect MIPs expression. Induction of
both MIP-1
and MIP-1ß by PA was associated with transcriptional
activation and mRNA stabilization, suggesting a dual molecular
mechanism of control. Iron chelation could be involved in MIPs
induction by PA because iron sulfate inhibited the process and the
iron-chelating agent, desferrioxamine, induced MIPs expression. We
propose the existence of a new pathway leading to inflammation
initiated by tryptophan catabolism that can communicate with the immune
system through the production of PA, followed by secretion of
chemokines by macrophages. These results establish the importance of PA
as an activator of macrophage proinflammatory functions, providing the
first evidence that this molecule can be biologically active without
the need for a costimulatory agent.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |